Begenik Huseyin, Aslan Mehmet, Dulger Ahmet Cumhur, Emre Habib, Kemik Ahu, Kemik Ozgur, Esen Ramazan
Department of Internal Medicine, Medical Faculty, Yuzuncu Yil University, Van, Turkey.
Department of Gastroenterology, Medical Faculty, Yuzuncu Yil University, Van, Turkey.
Arch Med Sci. 2015 Apr 25;11(2):346-52. doi: 10.5114/aoms.2015.50967. Epub 2015 Apr 23.
Serum leptin levels have been examined in various cancers, with conflicting results. However, there is limited information regarding serum leptin levels and insulin resistance in gastric cancer patients. Therefore, we aimed to investigate serum leptin levels, performance status, insulin levels and insulin resistance in patients with gastric cancer. In addition, we examined the relationship between these measurements and leptin levels.
Thirty-nine patients with gastric cancer and 30 control subjects were enrolled in the study. Serum leptin, total protein, albumin, growth hormone, insulin and glucose levels were measured. The homeostasis model assessment (HOMA) was used to assess insulin resistance.
Serum levels of insulin, glucose and growth hormone and insulin resistance were significantly lower in gastric cancer patients than controls (p < 0.05 for all). In the Pearson correlation analysis, insulin resistance was found to be significantly correlated with serum leptin levels in gastric cancer patients (r = 0.320, p = 0.047). We observed a significant negative correlation between performance status and insulin resistance in patients with cachexia (r = -0.512, p = 0.030), while no association was found in non-cachectic patients.
We concluded that serum leptin levels are significantly lower in gastric cancer patients. In addition, gastric cancer patients have decreases in insulin levels, insulin resistance and growth hormone levels. This study found a positive association between serum leptin levels and insulin resistance. Moreover, there is a negative association between serum leptin levels and growth hormone levels. Thus, low insulin and growth hormone levels may suppress the production of leptin in gastric cancer patients.
血清瘦素水平已在多种癌症中进行了检测，但结果相互矛盾。然而，关于胃癌患者血清瘦素水平与胰岛素抵抗的信息有限。因此，我们旨在研究胃癌患者的血清瘦素水平、身体状况、胰岛素水平和胰岛素抵抗。此外，我们还研究了这些测量值与瘦素水平之间的关系。
39例胃癌患者和30例对照者纳入本研究。检测血清瘦素、总蛋白、白蛋白、生长激素、胰岛素和葡萄糖水平。采用稳态模型评估（HOMA）来评估胰岛素抵抗。
胃癌患者的血清胰岛素、葡萄糖和生长激素水平及胰岛素抵抗均显著低于对照组（均P<0.05）。在Pearson相关性分析中，发现胃癌患者的胰岛素抵抗与血清瘦素水平显著相关（r=0.320，P=0.047）。我们观察到恶病质患者的身体状况与胰岛素抵抗之间存在显著负相关（r=-0.512，P=0.030），而非恶病质患者未发现相关性。
我们得出结论，胃癌患者的血清瘦素水平显著降低。此外，胃癌患者的胰岛素水平、胰岛素抵抗和生长激素水平均降低。本研究发现血清瘦素水平与胰岛素抵抗之间存在正相关。此外，血清瘦素水平与生长激素水平之间存在负相关。因此，低胰岛素和生长激素水平可能会抑制胃癌患者瘦素的产生。
